Worth reading
38Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Who is moving to which position
Resolved 2025年3月14日Incoming appointee
3 itemsScheduled Appointment Date2025年6月下旬開催予定の第162期定時株主総会後。新任取締役の選任は定時株主総会での承認を条件とし、代表取締役、役付取締役および業務執行取締役は同日開催予定の取締役会で選任予定
岩田 和行
Previous position執行役員 営業本部名古屋支店長
New positionDirector, Sales
桑野 敬市
Previous position執行役員 研究開発本部創薬研究所長
New position取締役 研究開発担当
本郷 陽太郎
Previous positionJP モルガン証券株式会社投資銀行本部ヴァイスチェアマン
New positionDirectors
Departing officer
3 itemsDate of departure2025年6月下旬開催予定の第162期定時株主総会日以降
佐野 省三Next role stated
Former Position常務取締役 営業担当
New position当社の顧問（非常勤）
高垣 和史Stepping down
Former Position取締役 研究開発担当
New positionNot disclosed
櫻井 美幸Stepping down
Former PositionDirectors
New positionNot disclosed
“Next role stated” means the document names the position the person holds after stepping down. It does not necessarily mean they are leaving the company.
Whether the incumbent will remain in office (whether they will retain their position)
佐野省三氏は取締役会に残らず、退任後に当社の顧問（非常勤）に就任予定。高垣和史氏、櫻井美幸氏の退任後の役職は記載なし
Directors after the change12Number
Shareholders’ meeting approval要する。2025年6月下旬開催予定の第162期定時株主総会に役員人事を付議予定This appointment will not be formally finalized until it is approved at the general meeting of shareholders.
Executive officers are responsible for day-to-day business execution and hold positions separate from directors under the Companies Act.Advisers, counselors and secondees remain with the company or group after stepping down from their positions.
| Item | Details |
|---|---|
| Resolution date | 2025年3月14日 |
| Scheduled Appointment Date | 2025年6月下旬開催予定の第162期定時株主総会後。新任取締役の選任は定時株主総会での承認を条件とし、代表取締役、役付取締役および業務執行取締役は同日開催予定の取締役会で選任予定 |
| Date of departure | 2025年6月下旬開催予定の第162期定時株主総会日以降 |
| Name of appointee | 岩田 和行, 桑野 敬市, 本郷 陽太郎 |
| Appointee's new position | Director, Sales, 取締役 研究開発担当, Directors |
| Appointee's previous position | 執行役員 営業本部名古屋支店長, 執行役員 研究開発本部創薬研究所長, JP モルガン証券株式会社投資銀行本部ヴァイスチェアマン |
| Name of departing officer | 佐野 省三, 高垣 和史, 櫻井 美幸 |
| Former position of departing officer | 常務取締役 営業担当, 取締役 研究開発担当, Directors |
| New position of departing officer | 当社の顧問（非常勤）, Not disclosed, Not disclosed |
| Whether the incumbent will remain in office | 佐野省三氏は取締役会に残らず、退任後に当社の顧問（非常勤）に就任予定。高垣和史氏、櫻井美幸氏の退任後の役職は記載なし |
| Number of directors after the change | 12 (including 4 outside directors) |
| Subject to Approval by the General Meeting of Shareholders | 要する。2025年6月下旬開催予定の第162期定時株主総会に役員人事を付議予定 |
Items this document does not state (9)
Appointee's date of birthYear the appointee joined the CompanyNumber of shares held by the appointeeReason for departureReason for changeReasons for appointmentFiling as an independent officerDetails of organizational changesChange in Corporate Governance Structure
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.No reason for the changes is provided.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.